Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:administered_by |
suspension
oral tablet extended-release tablet |
| gptkbp:approves |
gptkb:1968
gptkb:FDA |
| gptkbp:atccode |
N03 AF01
|
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
gptkb:Carbatrol
gptkb:Tegretol gptkb:Equetro |
| gptkbp:casnumber |
298-46-4
|
| gptkbp:category |
gptkb:D
|
| gptkbp:chemical_formula |
C15 H12 N2 O
|
| gptkbp:clinical_trial |
epilepsy treatment
bipolar disorder treatment trigeminal neuralgia treatment |
| gptkbp:contraindication |
MAO inhibitors
bone marrow suppression hypersensitivity to carbamazepine |
| gptkbp:discovered_by |
1960s
|
| gptkbp:formulation |
gptkb:tablet
suspension extended-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
carbamazepine
|
| gptkbp:interacts_with |
gptkb:warfarin
oral contraceptives certain antidepressants |
| gptkbp:lifespan |
25 to 65 hours
|
| gptkbp:mechanism_of_action |
sodium channel blocker
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:pharmacokinetics |
highly protein-bound
active metabolite is carbamazepine-10,11-epoxide analgesic effect anticonvulsant effect extensively metabolized in liver mood stabilizing effect |
| gptkbp:related_to |
gptkb:phenytoin
gptkb:lamotrigine gptkb:valproate |
| gptkbp:side_effect |
gptkb:stevens-johnson_syndrome
dizziness nausea drowsiness blurred vision liver dysfunction aplastic anemia toxic epidermal necrolysis hyponatremia |
| gptkbp:trade_mark |
gptkb:Carbatrol
gptkb:Tegretol gptkb:Equetro |
| gptkbp:used_for |
gptkb:epilepsy
bipolar disorder trigeminal neuralgia |
| gptkbp:bfsParent |
gptkb:CYP2_D6
gptkb:CYP3_A4 |
| gptkbp:bfsLayer |
4
|